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ABSTRACT
Objective: To elaborate recommendations to the vaccination of patients with rheumatoid arthritis (RA) in Brazil. 
Method: Literature review and opinion of expert members of the Brazilian Society of Rheumatology Committee of 
Rheumatoid Arthritis and of an invited pediatric rheumatologist. Results and conclusions: The following 12 recom-
mendations were established: 1) Before starting disease-modifying anti-rheumatic drugs, the vaccine card should be 
reviewed and updated; 2) Vaccines against seasonal inÀ uenza and against H1N1 are indicated annually for patients 
with RA; 3) The pneumococcal vaccine should be indicated for all patients with RA; 4) The vaccine against varicella 
should be indicated for patients with RA and a negative or dubious history for that disease; 5) The HPV vaccine should 
be considered for adolescent and young females with RA; 6) The meningococcal vaccine is indicated for patients 
with RA only in the presence of asplenia or complement de¿ ciency; 7) Asplenic adults with RA should be immu-
nized against Haemophilus inÀ uenzae type B; 8) An additional BCG vaccine is not indicated for patients diagnosed 
with RA; 9) Hepatitis B vaccine is indicated for patients with RA who are negative for antibodies against HBsAg; 
the combined hepatitis A and B vaccine should be considered; 10) Patients with RA and at high risk for tetanus, who 
received rituximab in the preceding 24 weeks, should undergo passive immunization with tetanus immunoglobu-
lin in case of exposure; 11) The YF vaccine is contraindicated to patients with RA on immunosuppressive drugs; 
12) The above described recommendations should be reviewed over the course of RA.
Keywords: rheumatoid arthritis, vaccination, immunization, adult.
© 2013 Elsevier Editora Ltda. All rights reserved.
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INTRODUCTION
Patients with rheumatoid arthritis (RA) are at increased risk 
for infections.1,2 Infectious outcomes in RA are among the 
major causes of death in those patients, and the mortality re-
lated to those events can be up to ten times that of the general 
population.3 Patients with severe disease and/or comorbidities 
are most often affected.1,4
Several factors have been associated with that increased 
susceptibility to infections. One of those major factors is the 
use of immunomodulators for the treatment of the disease 
itself, in particular biologics, whose indication has been 
increasingly frequent and early in the course of disease. 
The introduction of new agents in the therapeutic arsenal of 
rheumatology interferes with several points of the immune 
system.5
Knowing that vaccination is the most effective preventive 
measure for reducing the occurrence of infection at any age 
group, the vaccine chart should be reviewed and updated be-
fore starting either synthetic or biological disease-modifying 
anti-rheumatic drugs (DMARDs) (Table 1). However, that is 
often neglected in routine rheumatological practice, leaving 
a large number of patients unprotected against infectious 
diseases that could be prevented. Several studies have shown 
that the vaccine coverage of patients with rheumatic diseases 
worldwide is suboptimal.6–8
Some of the vaccines available can have their immunoge-
nicity reduced depending on the patient’s immunosuppression 
status; however, international experience has shown that the 
administration of most vaccines comprised in the vaccine 
calendar is safe, considering that they neither worsen the 
activity nor reactivate manifestations of rheumatic diseases.9
The present consensus aimed at reviewing the literature 
and elaborating recommendations for the indication of vac-
cines in patients with RA, considering the epidemiological 
scenario and the resources of medical care in Brazil. The pur-
pose of this document is to summarize the current position of 
the Brazilian Society of Rheumatology (SBR) on the subject, 
to guide Brazilian physicians, especially rheumatologists.
METHOD OF CONSENSUS ELABORATION 
The method for elaborating the recommendations included 
a literature review and the opinion of expert members 
of the SBR Committee of Rheumatoid Arthritis and of 
an invited pediatric rheumatologist. The bibliographic 
survey included publications in the MEDLINE, SciELO, 
PubMed and EMBASE databases up to February 2012. 
The recommendations were written and reassessed by all 
participants during multiple rounds of questioning and cor-
rections performed via internet. Based on the considerations, 
the experts provided recommendations on the vaccination of 
patients diagnosed with RA (Table 2).
Inactivated or Recombinant Vaccines
The great advantage of inactivated vaccines is the total lack 
of infectious potential of the pathogenic agent: such vaccines 
do not trigger the disease, but maintain the immunologic char-
acteristics of the agent. Inactivated or recombinant vaccines, 
however, have the disadvantage of inducing a suboptimal 
immune response, requiring sometimes the association of 
adjuvants or transporting proteins and the administration of 
booster shots.
Adhesion to the Brazilian guidelines is recommended for 
the following vaccines that do not contain live organisms: in-
À uenza vaccine (intramuscular – IM); pneumococcal vaccine 
(13V-conjugated and 23-polysaccharide); tetanus vaccine; 
diphtheria vaccine; pertussis vaccine; Haemophilus inÀ uenzae 
type B (Hib) vaccine; hepatitis A and B vaccine; poliomyelitis 
vaccine (inactivated – VIP); meningococcal vaccine; human 
papillomavirus (HPV) vaccine; typhoid fever vaccine (IM); 
and rabies vaccine.10 Such vaccines can be safely administered, 
preferentially 14 days before starting DMARDs, in an attempt 
to reach the expected immunogenicity. When the vaccine chart 
cannot be updated prior to the beginning of treatment, all those 
vaccines can be administered to patients with RA, even those on 
corticosteroids (CS) and/or synthetic or biological DMARDs, 
based on their safety demonstrated in several studies;9,11 the 
response, however, might be impaired.
Inﬂ uenza virus vaccine 
Respiratory infections are common among patients with RA 
and have high mortality rate.12 Vaccination against inÀ uenza 
has proved to reduce the number of hospital admissions and 
mortality due to respiratory infections in elderly patients, 
being effective even in patients on DMARDs.13
Response to the inÀ uenza vaccine seems not to be im-
paired in patients on anti-TNF agents, even when associated 
with methotrexate (MTX).14–16 However, one author has 
reported a reduced response to that vaccine in patients on 
inÀ iximab or etanercept associated with MTX.17 Likewise, 
one study conducted in Brazil assessing the vaccine against 
H1N1 inÀ uenza has found, in addition to a good safety pro¿ le, 
a reduction in the seroprotection of patients with RA, regard-
less of disease activity. Methotrexate was the only DMARD 
associated with a reduced response to that vaccine.11
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Table 1




18–26 27–49 50–59 60–64 ≥ 65 
Inﬂ uenza¥ 1 annual dose Public health units/ CRIE
Tdap: tetanus, diphtheria, 
pertussis¥
Complete basic vaccination schedule: booster shot with Tdap and, then, 
one dose of dT every 10 years#
Booster shot of 
dT every 10 
years
Public health units 
Acellular vaccine at 
private clinics
IPV (Salk)¥ Complete basic vaccination schedule: booster shot with 1 dose## CRIE/private clinics
Tdap + IPVϴ
Complete basic vaccination schedule: booster shot with Tdap from the age of 7 years onwards 
and, then, 1 dose of dT every 10 years# Private clinics 
HPV¥
3 doses (women) 




(polysaccharide)*,¥ 1 or 2 doses 1 dose CRIE/private clinics
Conjugated pneumococcal 
13** 1 dose or more** CRIE/private clinics
Conjugated meningococcal¥ 1 dose, even for individuals vaccinated during childhood or more than 5 years before Public health units 
Hepatitis A¥ 2 doses, minimum interval of 6 months CRIE/private clinics
Hepatitis B¥ 3 doses (0, 1 and 6 months) Public health units 
Combined hepatitis A and Bϴ 3 doses (0, 1 and 6 months) Private clinics
Varicella***,¥ 2 doses, 8-week interval (negative history for varicella-zoster virus infection or vaccination) CRIE/private clinics
Yellow fever*** 1 dose every 10 years for those living in endemic areas or traveling to such areas Public health units
Herpes-zoster***,¥ 1 dose Private clinics
Measles, mumps, 
rubella***,¥
Single dose if the vaccination schedule 
is complete. Two doses (minimum 
interval of 30 days) for those who had 
received one previous dose
1 dose Public health units
CRIE: reference center for special immunobiological drugs; dt: adult combined vaccine against diphtheria and tetanus; Tdap: combination vaccine with acellular pertussis of the adult type; IPV: inactivated 
polio vaccine; HPV: human papilloma virus.
¥For all individuals of that category who meet the age criteria and need immunization (with neither vaccination card nor evidence of previous infections).
ϴCombined vaccines, option: to reduce the number of injections.
*For patients with functional or anatomical asplenia or complement deﬁ ciency.
** For patients without a good response to the pneumococcal 23 vaccine.
*** Live, attenuated vaccines. Contraindicated to immunosuppressed individuals and pregnant women, except when the risks for acquiring the disease surpass the potential risks of vaccination. Greater care 
should be taken on the ﬁ rst vaccination.
#With incomplete or unknown basic vaccination schedule (fewer than 3 previous doses of dT, DTP or DTaP vaccines): complete the 3-dose schedule, administering 1 dose of Tdap and 1 or 2 doses of dT 
(schedule: 0–2–6 months) to provide 3 doses of the tetanus component. In both cases, if the Tdap vaccine cannot be used, replace it with the dT vaccine.
##Unvaccinated adults should receive primary vaccination with IPV. Adults without vaccination documentation should be considered unvaccinated. Two doses of IPV at 4–8-week interval are recommended; a 
3rd dose should be administered 6–12 months after the 2nd dose. Household contacts of immunosuppressed patients should be vaccinated.
There is also evidence of an impaired response to pneumo-
coccal and inÀ uenza vaccines when administered to patients 
on rituximab.13,18,19 The response to the inÀ uenza vaccine 
(including vaccine against inÀ uenza A and H1N1) is particu-
larly impaired when administered early, 4–8 weeks after the 
administration of rituximab. Thus, inÀ uenza vaccines should 
be administered before starting rituximab or 6 months after 
its ¿ rst infusion and 4 weeks before its next dose.20
The inÀ uenza vaccine is considered safe, and has been used 
in Brazil in annual campaigns for the population aged 60 years 
and over and for adults and children over the age of 6 months 
in special clinical situations, such as patients with RA.10 It is 
contraindicated only to patients with history of allergy to egg 
or to the vaccine itself, as well as to those who had Guillain-
Barré syndrome up to 6 weeks after receiving that vaccine.
Seasonal and H1N1 inÀ uenza vaccines are indicated an-
nually to patients with RA.
Pneumococcal vaccine 
Bacterial infections of the respiratory tract are more common 
in patients diagnosed with RA as compared with the general 
population and contribute to increase morbidity and mortal-
ity.21,22 Thus, vaccination against Streptococcus pneumoniae 
(pneumococcus) is highly relevant for patients with RA.
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Table 2
Recommendations of the Brazilian Society of Rheumatology on vaccination of patients diagnosed with rheumatoid arthritis
Recommendation 1
Before starting synthetic or biological DMARDs, the vaccine card should be reviewed and updated.
Recommendation 2: inﬂ uenza vaccine 
Vaccines against seasonal inﬂ uenza and against H1N1 are indicated annually for patients with RA. 
Recommendation 3: pneumococcal vaccine
The pneumococcal vaccine should be indicated for all patients with RA and can be more effective when administered before starting synthetic or 
biological DMARDs. When patients are on immunosuppressive agents, the response to vaccine should be assessed. 
Recommendation 4: HPV vaccine 
The HPV vaccine should be considered for adolescent and young females with RA, preferably before starting sexual life.
Recommendation 5: meningococcal vaccine
The meningococcal vaccine is indicated for patients with RA only in the presence of asplenia or complement deﬁ ciency. It should also be considered in 
the presence of outbreaks and severe immunosuppression.
Recommendation 6: Haemophilus inﬂ uenzae type B vaccine
Asplenic adults with RA should be immunized against Haemophilus inﬂ uenzae type B.
Recommendation 7: hepatitis A and B vaccine
Hepatitis B vaccine is indicated for patients with RA who are negative for antibodies against HbsAg, preferably before starting treatment with biological 
DMARDs. The combined hepatitis A and B vaccine should be considered.
Recommendation 8: Combined vaccine against diphtheria, tetanus and acellular pertussis (DTaP/Tdap) and combined vaccine against diphtheria and 
tetanus (dT)
Patients on immunosuppressive drugs should undergo the same vaccine schedule recommended for healthy individuals. Patients with RA and at high risk 
for tetanus, who received rituximab in the preceding 24 weeks, should undergo passive immunization with tetanus immunoglobulin in case of exposure.
Recommendation 9: BCG vaccine
An additional BCG vaccine is not indicated for patients diagnosed with RA, because all the Brazilian population is already vaccinated right after birth.
Recommendation 10: vaccines comprising live attenuated viruses
These vaccines should be administered 2−4 weeks before beginning immunosuppressive therapy, 2 weeks after discontinuation of synthetic DMARDs, 
4 weeks after discontinuation of CS, 12 weeks after discontinuation of immunoglobulins, cytotoxic drugs or alkylating agents. For biological DMARDs, 
a period corresponding to 4 half-lives should be observed after drug suspension.
Recommendation 11: vaccine against varicella
The vaccine against varicella should be indicated for patients with RA and a negative or dubious history for that disease and/or previous vaccination, 
preferably before starting immunosuppression, or when patients are on low CS doses and usual MTX doses.
Recommendation 12: vaccine against YF
The YF vaccine is contraindicated for patients with RA on immunosuppressive drugs, such as synthetic and biological DMARDs. Physicians should 
provide their patients with information on endemic areas, individualized risk of infection, and each patient’s immunosuppression status, so that the 
indication of vaccine to that population in speciﬁ c and very particular situations can be assessed.
Recommendation 13
The above described recommendations should be reviewed over the course of RA. Whenever possible, the vaccine status should be updated, even when 
synthetic DMARDs are used and preferably before starting biological therapy.
DMARD: disease-modifying anti-rheumatic drug; RA: rheumatoid arthritis; HPV: human papilloma virus; CS: corticosteroid; YF: yellow fever; BCG: Bacillus Calmette-Guérin.
In Brazil, the pneumococcal vaccine available for adults 
is the 23-valent polysaccharide vaccine (Pn23), a polyva-
lent vaccine prepared from puri¿ ed polysaccharides of the 
bacterial capsule, containing 23 serotypes of Streptococcus 
pneumoniae.10 However, it is associated with low immune 
response when compared with conjugated formulations 
(pneumo 7, 10 and 13). 
The isolated use of MTX or its combination with some 
anti-TNF agents (adalimumab, etanercept and inÀ iximab) can 
reduce the ef¿ cacy of the vaccine, while the isolated use of 
those biologics does not inÀ uence the response to vaccine.15,17 
In 2011, that ¿ nding was con¿ rmed by a study performed with 
conjugated vaccine against 7 pneumococcal serotypes (Pn7) in 
patients with RA and spondyloarthritides.23 A single administra-
tion of the Pn23 vaccine offers up to 10-year protection against 
the development of pneumococcal pneumonia in patients with 
RA on MTX.24 The safety pro¿ le seems appropriate, which was 
a conclusion common to all those studies.
The additional bene¿ t of the association of the Pn23 
vaccine with conjugated vaccines has not yet been shown 
in patients with RA, but the response to the Pn23 vaccine 
should be monitored, mainly when administered to patients 
on synthetic or biological DMARDs. When inappropriate, the 
administration of a conjugated vaccine should be indicated, 
knowing that it is much more immunogenic than the Pn23 
vaccine.
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Usually, the Pn23 vaccine is well tolerated. The adverse 
events are mild, of short duration and limited to the vaccine 
application site. More intense local reactions are most often 
observed after early revaccination, especially in individuals 
with high titers of antibodies against the pneumococcus.10
In Brazil, the Pn23 vaccine is used to immunize institu-
tionalized individuals aged 60 years and over. In that popula-
tion, a single dose of the vaccine is administered with only 
one booster shot 5 years after the initial dose. It can also 
be indicated to individuals with chronic diseases, such as 
heart diseases, lung diseases, diabetes, and other conditions 
considered to increase the risk for pneumococcal disease, 
such as functional or anatomical asplenia and complement 
de¿ ciency.10,25
The pneumococcal vaccine should be indicated for all pa-
tients with RA, and can be more effective when administered 
before beginning synthetic or biological DMARDs.
HPV vaccine 
The HPV is a sexually transmitted virus, highly prevalent in 
Brazil.26 There are more than 100 types of HPV, of which ap-
proximately 30 types affect men and women. HPV infection 
is the major risk factor for uterine cervix cancer, being also 
associated with tumors of the penis, anus, mouth and throat. 
HPV also causes genital warts or condyloma acuminatum.27
The quadrivalent vaccine is highly effective to prevent 
infections by the subtypes 16 and 18 (the most oncogenic 
subtypes) and 6 and 11 (responsible for genital warts). Several 
countries recommend vaccination against HPV in young 
women, ideally before initiating sexual activity. The Brazilian 
Ministry of Health does not recommend that as a public health 
guideline,28 but the Brazilian Agency of Sanitary Surveillance 
(ANVISA) indicates that vaccination in women aged 11 to 
26 years. That vaccine is administered via IM, in 3 doses on 
the months 0, 1–2 and 6.27 Few adverse events of that vaccine 
have been described, and some patients can have mild local 
reactions.
Unlike systemic lupus erythematosus, a condition in which 
the incidence of HPV infection is known to be increased,26 
in RA, data are less well-known. In 2008, a Mexican study 
showed that 1 in every 3 women with RA can have HPV in-
fection, and more than 90% of the patients have the high-risk 
viral subtype.29
Studies on the ef¿ cacy and safety of the HPV vaccine in pa-
tients with RA or other rheumatic diseases still lack. However, 
because the vaccine contains no viral genetic material and its 
basis is L1 capsid proteins, it is considered safe for patients 
with autoimmune diseases, even when immunosuppressed. 
Other international societies of specialists have suggested 
that patients with autoimmune diseases might bene¿ t from 
that vaccine.9
The HPV vaccine should be considered for adolescents 
and young women with RA, preferably before initiating their 
sexual life.
Meningococcal vaccine 
Meningococcal vaccine is indicated to prevent invasive disease 
caused by Neisseria meningitidis, especially in conditions of 
particular susceptibility to meningococcus, such as patients 
with asplenia and complement de¿ ciency. The meningococ-
cal serogroup C conjugate vaccine is currently available at the 
Brazilian public health system. It can be administered via IM 
from the age of 2 months onward, with no upper age limit.10 
Although the incidence of meningococcal disease in adults is 
low, vaccination is recommended when possible or in case of 
outbreaks, or travels that entail risk. The quadrivalent menin-
gococcal conjugate vaccine (types A.C, W135 and Y) should 
be considered an option to immunize adolescents and adults.
Studies on the ef¿ cacy and safety of the meningococcal 
vaccine in patients with RA still lack. The experience is higher 
with pediatric patients. It has been proven safe and effective 
in children and adolescents with juvenile idiopathic arthritis 
(JIA), even when on immunosuppressive drugs.30,31 The adverse 
events that might occur in the general population are local 
reactions, low fever and irritability.
The meningococcal vaccine is indicated for patients with 
RA, mainly those with asplenia and complement de¿ ciency.
Haemophilus inﬂ uenzae type B vaccine
The Hib is a capsulate bacterium that causes invasive diseases, 
such as meningitis, epiglottitis, septicemia, osteomyelitis and 
arthritis. Patients with RA and other rheumatic diseases are at 
greater risk of developing infections related to that bacterium, 
having, thus, indication for immunization.32
Similarly to the meningococcal vaccine, the Hib vaccine is 
conjugated, comprises polysaccharides of the bacterial capsule, 
and is administered via IM. That vaccine is part of the Brazilian 
vaccination calendar, and should be administered to children 
and adolescents up to the age of 19 years.33
Patients with rheumatic disease and indication for vac-
cination against Hib should be immunized as soon as their 
diagnosis is made, preferentially before beginning the immu-
nosuppressive therapy, because of the possible interference 
with vaccine response.34
In addition to the indication of Hib vaccination for chil-
dren and adolescents with rheumatic disease, asplenic adults 
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with RA should also be immunized. Studies on safety and 
ef¿ cacy in patients with RA still lack.13
Hepatitis A and B vaccine 
There is no evidence that infections by hepatitis A (HVA) 
or B (HVB) viruses are more prevalent in patients with RA. 
However, screening of liver diseases and preventive measures 
against liver diseases are highly recommended in that group 
of patients due to their frequent use of hepatotoxic drugs, 
and the fact that Brazil has changed its endemic situation 
of hepatitis A, being currently considered of intermediate 
risk, meaning an increase in the number of susceptible adult 
individuals.35
In Brazil, vaccines available against HVA and HVB are 
produced by using recombinant DNA technology, and the 
combined formulation of both exist. The hepatitis A and B 
vaccines are considered safe.10 They might cause local reac-
tions, fever in the ¿ rst 24 hours, fatigue, headache, irritability 
and gastrointestinal discomfort.
In RA, the safety and ef¿ cacy of the hepatitis B vaccine 
have been assessed in a prospective study.36 Vaccination 
against hepatitis B has been associated with neither a signi¿ -
cant deterioration of any clinical or laboratory measure of 
the disease, nor other important adverse events. Regarding 
ef¿ cacy, 15 of 22 (68.2%) patients responded to vaccination, 
with titers of antibodies against HBsAg of 10 IU/L after 7 
months. The response rate was lower than that of the general 
population (85%–95%). In addition, the use of anti-TNF 
agents might signi¿ cantly reduce the vaccine response.37 
Studies of HVA in patients with RA still lack.
The hepatitis B vaccine should be indicated for patients 
with RA when their serology against HBsAg is negative, pref-
erably before beginning treatment with biological DMARDs.
The hepatitis A vaccine should be indicated for patients 
with RA because of their increased susceptibility to infection 
by that virus in our population, and because of the additional 
risk of hepatitis A-associated macrophage activation syn-
drome (MAS) and fulminant hepatitis in patients on chronic 
non-steroidal anti-inÀ ammatory drugs (NSAIDs).38,39
Combined vaccine against diphtheria, 
tetanus and acellular pertussis (DTaP/Tdap) 
and combined vaccine against diphtheria 
and tetanus (dT)
The DTaP is a combined vaccine against diphtheria, tetanus 
and pertussis, in which the pertussis component is acellular.34 
Adult and elderly individuals with a complete basic vac-
cination schedule should receive a booster shot with Tdap 
(combination vaccine with acellular pertussis of the adult 
type) every 10 years. The combined vaccine against diphthe-
ria and tetanus (dT) is indicated for adolescents and adults.
Individuals with an incomplete basic vaccination schedule 
(who have received fewer than 3 doses of the tetanus compo-
nent during their lives) should complete their 3-dose schedule, 
receiving 1 dose of Tdap and 1 or 2 doses of dT according 
to the 0–2–6-month schedule. The Tdap vaccine is strongly 
indicated for the elderly. Individuals who have received the 
dT vaccine at least 2 years before should receive 1 dose of 
the Tdap vaccine.34
The Brazilian Ministry of Health recommends the vac-
cine with whole cell pertussis (DTP for children or dT for 
adolescents and adults). The World Health Organization 
(WHO) and the Pan-American Health Organization continue 
to recommend the DTP vaccine for most countries, assuring 
its ef¿ cacy and safety. The DTaP vaccine is not part of the 
routine calendar. Several developed countries indicate the 
acellular forms as follows: DTaP for individuals < 7 years 
and Tdpa for adolescents and adults.
After completing the vaccination schedule, the vaccine 
should be administered every 10 years, and, in case of preg-
nancy or wounds suspected of causing tetanus, every 5 years.
The vaccines against tetanus, diphtheria and pertussis are 
safe for adults and children with rheumatic diseases. The same 
vaccination schedule of healthy individuals is recommended 
for patients on immunosuppressive drugs.
Patients with RA and at high risk for tetanus, who received 
rituximab in the preceding 24 weeks, should undergo pas-
sive immunization with tetanus immunoglobulin in case of 
exposure.18,19
LIVE ATTENUATED VACCINES
This group includes the following vaccines: MMR (measles, 
mumps and rubella) triple vaccine; Bacillus Calmette-Guérin 
(BCG) vaccine; vaccine against inÀ uenza (nasal); vaccine 
against varicella; vaccine against herpes zoster; typhoid fever 
vaccine; vaccine against poliomyelitis (oral polio vaccine – 
OPV); vaccine against smallpox; and vaccine against yellow 
fever (YF). 
The Brazilian guidelines for vaccination with live attenu-
ated vaccines against MMR, varicella and booster shot of YF 
should be applied to patients with RA, except when they are 
known to be immunosuppressed, on high doses of CS, alkyl-
ating agents and/or biologics, until further data are available. 
Those vaccines can be used for rheumatologic patients on usual 
doses of synthetic DMARDs.
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Vaccines in this group should be preferably indicated 2–4 
weeks before beginning the immunosuppressive therapy, to 
assure that viral replication is over before the change in the 
patient’s immune competence due to the use of the medication. 
Otherwise, when the immunosuppressive treatment has already 
started, vaccination should be postponed for at least 1 month 
after CS therapy discontinuation, 3 months after cytotoxic 
and human immunoglobulin treatment discontinuation, and 6 
months after rituximab discontinuation. For the other biologi-
cal DMARDs, a period corresponding to 4 half-lives should be 
observed after drug suspension.
However, some speci¿ c situations, such as the occasional 
use of the YF vaccine in the population of endemic areas, should 
be considered.40
BCG vaccine 
Mycobacterium tuberculosis infection remains the most lethal 
infectious disease in the world, accounting for approximately 
1.7 million deaths per year. Brazil ranks the 17th position out of 
the 22 countries responsible for 80% of all cases of tuberculosis 
(TB) in the world.10,41 Patients with RA are at increased risk 
for TB, especially with the advent of anti-TNF-alpha therapy. 
Patients with RA on synthetic DMARDs have an incidence 
of TB 2- to 10-times greater than that of the general population. 
When patients are on TNF-alpha inhibitors, their incidence of 
TB is 6 to 10 times greater than that of patients who are not 
on biologics; in addition, their rate of TB is 30 times higher 
than that of the general population, reaching 144 per 100,000 
person-years.41 If preventive measures against TB are not 
adopted before the use of anti-TNF-alpha therapy, the risk is 
even higher.43
The BIOBADA Brasil, the Brazilian registry of patients 
with rheumatic diseases on biologics, shows 3 cases of TB out 
of 466 patients with RA on anti-TNF-alpha therapy.22
The BCG vaccine, the only licensed vaccine against 
TB, is elaborated from attenuated bacteria of bovine origin 
(Mycobacterium bovis), which is similar to the microorganism 
causing TB (Mycobacterium tuberculosis).10
In Brazil, the BCG vaccine is primarily indicated for chil-
dren aged 0 to 4 years, being mandatory for those under the age 
of 1 year. According to most studies, its ef¿ cacy is 50% (range, 
10%–66%) for all forms of the disease, but it is insuf¿ cient to 
protect against the pulmonary forms (ef¿ cacy lower than 50% 
in the majority of the most consistent studies). It protects against 
tuberculous meningitis, disseminated forms of the disease 
(range of ef¿ cacy, 68%–100%), and leprosy. The immunity is 
maintained for 10–15 years. The BCG vaccine does not protect 
individuals already infected with Mycobacterium tuberculosis.
An additional BCG vaccine for patients with RA is not in-
dicated, because, in most of those patients, TB is due to disease 
reactivation or new infection, forms that the vaccine does not 
prevent. In addition, the ef¿ cacy of the BCG vaccine has not 
been proven in adults. The fact that it has an attenuated mycobac-
terium is another relevant factor supporting its contraindication 
in patients with RA.10,41
Vaccine against varicella and herpes zoster
Patients with RA are at higher risk of developing herpes zoster 
infection versus general population.44 That risk is even greater 
in patients on CS therapy and biologics.44,45
The vaccine against varicella contains live attenuated viruses 
derived from the Oka strain, and is administered subcutane-
ously.10 It has been proven to reduce the number of infections 
and complications, such as postherpetic neuralgia in immuno-
suppressed patients (on chemotherapy and post-transplantation), 
as compared to those reporting infection with the wild virus in 
childhood.10,46
The vaccine against herpes zoster, still not available in 
Brazil, also had its ef¿ cacy con¿ rmed in adults over the age of 
60 years47 and in patients with chronic inÀ ammatory diseases 
over the age of 50 years.48 According to those studies, that vac-
cine is indicated for patients over the age of 50 years and diag-
nosed with rheumatic diseases based on the American College 
of Rheumatology criteria, even when they are on DMARDs 
at usually recommended doses.49 The use of low doses of im-
munosuppressive drugs, such as MTX (< 0.4 mg/kg/week) and 
azathioprine (< 3.0 mg/kg/day), is not considered suf¿ ciently 
immunosuppressive to jeopardize that vaccine’s safety, not 
constituting a contraindication to its administration.49
The vaccine against varicella should be indicated for pa-
tients with RA and with a negative or dubious history for that 
disease and/or previous vaccination, preferably before starting 
immunosuppression. It is contraindicated when patients are 
immunosuppressed, receiving the following: high doses of 
systemic CS (> 20 mg of prednisone per day or equivalent) for 
2 weeks or longer; pulse therapy; cytotoxic or alkylating agents; 
synthetic DMARDs at doses above those recommended; or im-
munobiological therapy.50
The vaccine against varicella might be indicated for patients 
with stable disease on low CS doses and usual MTX doses. If 
either the virus or infectious symptoms persist after vaccination, 
treatment with acyclovir is a possibility.49,50
Vaccine against yellow fever
Yellow fever is a noncontagious viral hemorrhagic febrile 
disease, transmitted by the bite of insects, especially those 
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of the Aedes and Haemagogus genera.51 In Brazil, the endemic 
area comprises mainly the Northern and West-Central regions, 
corresponding to approximately 68% of the territory.52 The 
overall lethality ranges from 5%–10%. It is estimated that 
only 10% of the cases are severe forms, associated with high 
lethality (range, 40%–60% of the cases). There is no speci¿ c 
treatment for the disease, the YF vaccine being the major 
preventive measure.51
The 17D vaccine against YF provides protection for at 
least 10 years, and even for the entire life.52,53 Within 30 days, 
more than 90% of vaccinated individuals develop antibodies 
against the disease.54 Of those individuals, 98%–100% become 
immunized.55,56
The YF vaccine is contraindicated to patients with RA 
on immunosuppressive drugs, because it is a live, attenuated 
vaccine, and there is risk of an uncontrolled vaccine viral 
replication.9,54,57 Cases of YF vaccine-associated viscerotropic 
disease have been reported in patients with systemic lupus 
erythematosus and rheumatic polymyalgia.58í60 
Another factor to be considered is the seroconversion 
ability of those patients, which is inversely proportional to the 
immunosuppression degree.57 
Anaphylaxis secondary to the YF vaccine is another 
relevant aspect, occurring at the frequency of 0.8 to 1.8 per 
100,000 doses, being attributed to allergy to egg or to the 
gelatin used in the vaccine’s production.61,62 The most relevant 
severe adverse events are YF vaccine-associated neurotropic 
and viscerotropic diseases,52,54,63 having the latter an expected 
lethality of around 60%.54
Only 2 studies have assessed the response to YF vaccina-
tion in rheumatic patients on immunosuppressive agents and 
their adverse events.40,64
Regarding adverse events in rheumatic patients, the only 
existing study has reported a case series of 70 patients with 
several rheumatic diseases, who had been inadvertently im-
munized with the YF vaccine. All of them had already been 
previously vaccinated against YF. Of the 70 patients, 16 
(22.5%) reported minor adverse events, a ¿ gure compatible 
with that expected for the healthy population.40 
Regarding the immune response in rheumatic patients, a 
study has assessed 17 patients with RA on biological therapy, 
who received the YF vaccine. Comparing the antibody titers 
between patients and controls, a trend of reduced response in 
the group of patients with RA was observed, although a sta-
tistical analysis could not be performed because of the small 
number of patients.64
The WHO recommends vaccination of the population 
residing in endemic areas and of travelers to those regions, 
with a boost every 10 years.53 The current recommendation 
is that immunosuppressed patients should not be vaccinated 
against the disease.9,65 Thus, the YF vaccine is contraindicated 
to patients with RA on immunosuppressive drugs, including 
synthetic and biological DMARDs.
Vaccination against YF in patients with RA living in endem-
ic areas, close to the wild or who will be exposed during work 
is controversial, and, so far, no consensus has been achieved. 
A risk-bene¿ t analysis requires considering whether the risk of 
contracting the natural infection é higher than that of experienc-
ing a severe adverse event.57 Physicians should provide their 
patients with information on endemic areas, individualized 
risk of infection, and each patient’s immunosuppression status, 
so that the indication of vaccine to that population in speci¿ c 
and very particular situations can be assessed; the decision to 
vaccinate, however, is up to each patient.65
Vaccine against measles, mumps and rubella 
(MMR or triple viral vaccine)
The triple viral vaccine is a combined vaccine containing 
live, attenuated viruses, and which protects against measles, 
mumps and rubella (MMR). It is administered subcutaneously. 
Usually, the MMR vaccine causes few adverse events, being 
well tolerated. All individuals should receive or have received 
2 doses of the MMR vaccine, with a minimum interval of 1 
month. More than 2 doses are not necessary. 
It is worth noting that, as the MMR vaccine became part 
of the of¿ cial Brazilian vaccination calendar only in 2003, 
most patients with RA might not have received that vaccine. 
The MMR vaccine is indicated to childbearing age women, 
because of the risk of congenital rubella, and to all patients with 
a negative serology or who travel to endemic areas, except for 
the restrictions applied to vaccines of live, attenuated viruses.
Only 2 studies have assessed the safety of the MMR vaccine 
(booster shot) to patients with JIA. Both studies evidenced ap-
propriate safety and immunogenicity.66,67 Studies on the safety 
of the MMR vaccine to adults with RA still lack.
CONCLUSIONS
Safe and effective vaccination is crucial for patients with RA, 
because of their increased risk of infection. Vaccination is 
no longer exclusive to children, and currently adolescents, 
adults, pregnant women and the elderly have speci¿ c and 
individualized immunization programs.
The vaccine chart should be updated as soon as the diagno-
sis of RA is established, preferably before starting DMARDs. 
The recommendations of the SBR Committee for RA followed 
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the Brazilian guidelines for vaccination, because those guide-
lines consider local epidemiology, resources and health poli-
cies. Vaccines against Hib, pneumococcus, meningococcus, 
HPV, hepatitis A, and varicella-zoster virus (VZV) are not 
universally recommended in the Brazilian guidelines, but are 
considered important in the management of those patients. 
There are speci¿ c recommendations for those vaccines.
Several recommendations proposed have not been based 
on the best degree of scienti¿ c evidence, and some limitations 
should be highlighted in the present study. To properly assess 
the ef¿ cacy of a certain vaccine, studies aimed at assessing 
the number of infections prevented with the intervention 
should have been conducted. That type of study cannot be 
performed because of the number of patients required, the 
follow-up time necessary, and ethical issues; thus, the results 
analyzed in this study were based on intermediate outcomes 
(immunogenicity). 
Usually, vaccines have good immunogenicity in patients 
with RA, except for some conditions depending on the type 
and dose of the immunosuppressive treatment and the type of 
vaccine. Patients on MTX showed a reduced response to the 
Pn23, while the T-dependent response to conjugated or live, 
attenuated vaccines was considered adequate. Responses to 
several vaccines (inÀ uenza, VZV) were reduced in patients on 
high doses of either CS or azathioprine. The use of rituximab 
is related to a reduction in the T-dependent and T-independent 
responses to vaccines. To yield an adequate and safe immune 
response, vaccination should be ideally performed before the 
introduction of immunosuppressive drugs. 
Regarding safety, both disease activity and adverse events 
were studied. It is worth emphasizing that there is no study 
with satisfactory statistical power to assess adverse events 
in patients with RA for most vaccines. However, the admin-
istration of inactivated vaccines during the use of CS, usual 
doses of DMARDs, and anti-TNF seems to be safe. Because 
data on vaccines with live components are still scarce, their 
indication is limited to booster doses of the varicella, YF and 
MMR vaccines, apparently safe in patients on regular doses 
of MTX and low doses of CS. The ¿ rst dose of those vac-
cines should be administered before starting the treatment of 
patients with RA, observing the already described intervals.
This study aimed at establishing consensual guidelines for 
the vaccination of patients diagnosed with RA, by using evi-
dence obtained from the best studies available, to standardize 
the indication of immunization by rheumatologists and other 
professionals managing those patients, considering speci¿ c 
aspects of the Brazilian reality. We believe that implementing 
those guidelines is perfectly feasible in Brazil, considering 
that the Brazilian Immunization Program (PNI) is one of the 
most successful public health initiatives in Brazil.
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pelo risco da rubéola congênita, ou para todos os pacientes 
que apresentem sorologia negativa ou viajarem para áreas 
endêmicas, salvo as restrições já colocadas para as vacinas 
de vírus vivos atenuadas. 
Há apenas dois estudos que avaliaram a segurança da SCR 
(dose de reforço) em pacientes com AIJ. Ambos evidenciaram 
segurança e imunogenicidade adequadas.66,67 Não há estudos 
em adultos com AR.
CONCLUSÕES
Vacinação segura e e¿ caz é crucial para pacientes com AR, 
dado o risco aumentado de infecção. Vacinação deixou de 
ser exclusividade da criança, e hoje adolescentes, adultos, 
gestantes e idosos têm programas de imunização especí¿ cos 
e individualizados. 
A atualização do cartão vacinal deve ser indicada tão logo 
se realize o diagnóstico de AR e, preferencialmente, antes da 
introdução de DMCD. As recomendações da Comissão de 
AR da SBR seguiram as diretrizes nacionais de vacinação, 
uma vez que esses documentos levam em consideração a 
epidemiologia local, recursos e políticas de saúde. Vacinas 
contra Hib, pneumococo e meningococo, HPV, hepatite A e 
vírus varicela-zóster (VZV) não são universalmente incluídas 
nas diretrizes nacionais, mas são considerados importantes no 
manejo desses pacientes. Para essas vacinas, há recomenda-
ções especí¿ cas.
Muitas dessas recomendações desenvolvidas não têm 
como base o melhor grau de evidência cientí¿ ca, e algumas 
limitações devem ser ressaltadas no presente trabalho. Para 
avaliar adequadamente a e¿ cácia de determinada vacina, seria 
necessária a condução de estudos com o objetivo de avaliar 
número de infecções evitadas com a intervenção. Como esse 
tipo de estudo é inviável pelo número de pacientes necessários, 
pelo tempo de acompanhamento e pelos condicionamentos 
éticos, os resultados analisados baseiam-se em desfechos 
intermediários (imunogenicidade). 
Em geral, a imunogenicidade das vacinas é boa em pacien-
tes AR, salvo algumas exceções, a depender do tipo e da dose 
de tratamento imunossupressor, bem como do tipo de vacina. 
Pacientes utilizando MTX apresentaram redução na resposta 
da Pn23, enquanto a resposta T dependente para vacinas 
conjugadas ou vivas atenuadas foi considerada adequada. As 
respostas a várias vacinas (gripe, VZV) foram reduzidas em 
pacientes em uso de altas doses de CE ou azatioprina. O uso de 
rituximabe está relacionado à redução da resposta às vacinas 
tanto de células T independentes quanto T dependentes. Para 
viabilizar uma resposta adequada com segurança, o ideal é 
que a vacinação ocorra antes de drogas imunossupressoras 
serem introduzidas. 
Do ponto de vista de segurança, tanto a atividade da doença 
quanto os eventos adversos foram estudados. Não existem es-
tudos com poder estatístico satisfatório para observar eventos 
adversos em população de pacientes de AR para a maioria das 
vacinas. No entanto, a administração das vacinas inativadas 
parece ser segura durante a utilização de CE, DMCD em 
doses usuais e anti-TNF. Quanto às vacinas de componentes 
vivos, como os dados ainda são escassos, sua indicação ¿ ca 
limitada às doses de reforço das vacinas contra varicela, FA 
e SCR, aparentemente seguras em pacientes utilizando doses 
regulares de MTX e baixas doses de CE. A primeira dose dessas 
vacinas deve geralmente ser administrada antes do início do 
tratamento dos pacientes com AR, respeitando os intervalos 
já descritos anteriormente.
O propósito ¿ nal deste trabalho foi estabelecer diretrizes 
consensuais para vacinação nos pacientes com diagnóstico 
de AR, utilizando evidências obtidas nos melhores estudos 
disponíveis, a ¿ m de homogeneizar a indicação de imuniza-
ções pelos reumatologistas e demais pro¿ ssionais que lidam 
com esses pacientes, considerando aspectos especí¿ cos da 
realidade brasileira. Acreditamos que a implementação dessas 
orientações é perfeitamente viável no Brasil, tendo em vista 
que o Programa Nacional de Imunizações (PNI) é uma das 
iniciativas de saúde pública mais bem-sucedidas em nosso país.
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